DXC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
DXC Technology Co is not a strong buy at this time for a beginner investor with a long-term focus. While the company has made strides in AI innovation and has shown improvement in net income and EPS, the overall financial performance is mixed, with declining revenue and gross margin. Additionally, technical indicators and analyst ratings suggest a neutral to bearish outlook. The lack of strong trading signals and the absence of significant positive momentum in the stock's price trend further support a hold recommendation.
The MACD is positive and expanding, indicating some bullish momentum. However, the RSI is neutral at 56.177, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support and resistance levels suggest limited upside potential, with resistance at 12.265 and support at 11.612. Overall, the technical outlook is mixed, leaning slightly bearish.
DXC has been recognized on Fortune's America's Most Innovative Companies list, launched new AI-focused initiatives like Xponential and LabX, and opened AI and customer experience centers in key locations. These efforts highlight the company's focus on innovation and AI integration.
The company's Q4 revenue guidance was disappointing, and the mid-point of the FY revenue guide was lowered. Analysts have mixed to negative ratings, with one firm lowering its price target to $13 and maintaining an Underperform rating. Additionally, the stock has a 60% chance of declining in the short term based on candlestick analysis.
In 2026/Q3, revenue dropped by -0.96% YoY to $3.19 billion, and gross margin decreased by -1.72% YoY to 14.9%. However, net income increased significantly by 87.72% YoY to $107 million, and EPS rose by 96.77% YoY to 0.61. The financial performance shows mixed results, with strong profitability improvements but declining revenue and margins.
Analysts have a neutral to bearish outlook on DXC. BMO Capital raised its price target to $17 but noted challenges in achieving revenue stability. Wolfe Research lowered its price target to $13 and maintained an Underperform rating, citing softer-than-expected Q4 guidance.
